메뉴 건너뛰기




Volumn 48, Issue 1237, 2006, Pages 51-52

Conivaptan (Vaprisol) for hyponatremia
[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CALCIUM; CLARITHROMYCIN; CONIVAPTAN; DEMECLOCYCLINE; ITRACONAZOLE; RITONAVIR; SODIUM; VANILLOID RECEPTOR 2; VASOPRESSIN ANTAGONIST; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR;

EID: 33745933142     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey
Times cited : (6)

References (3)
  • 1
    • 0035856509 scopus 로고    scopus 로고
    • Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
    • J Udelson et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104:2417.
    • (2001) Circulation , vol.104 , pp. 2417
    • Udelson, J.1
  • 2
    • 33744963977 scopus 로고    scopus 로고
    • Efficacy and safety of oral conivaptan: A V1A/V2 vasopressin-receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
    • JK Ghali et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin-receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91:2145.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 2145
    • Ghali, J.K.1
  • 3
    • 22344453079 scopus 로고    scopus 로고
    • CYP3A and drug interactions. Med Lett Drugs Ther 2005; 47:54.
    • CYP3A and drug interactions. Med Lett Drugs Ther 2005; 47:54.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.